HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Cheng, L. Articles by Freeman, W. R. Search for Related Content PubMed PubMed Citation Articles by Cheng, L. Articles by Freeman, W. R.

Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir

¹From the Shiley Eye Center, University of California San Diego, La Jolla, California; the ²Department of Medicine, San Diego VA Healthcare System and University of California San Diego, La Jolla, California; and ³Cirrus Pharmaceuticals, Durham, North Carolina.

PURPOSE. In an earlier study, a novel intraocular drug-delivery system was reported in which hexadecyloxypropyl-phospho-ganciclovir (HDP-P-GCV) was used as a prototype. The hypothesis was that many biologically effective compounds could be modified to crystalline lipid prodrugs and could be delivered directly into the vitreous in a long-lasting, slow-release form. This study was undertaken to characterize this new drug-delivery system further, by using small particles of HDP-P-GCV and hexadecyloxypropyl-cyclic cidofovir (HDP-cCDV).

METHODS. HDP-P-GCV was microfluidized into 4.4-µm (median) particles, injected into rabbit vitreous. The vitreous drug level was then measured at different time points. Crystalline HDP-cCDV was synthesized, suspended in 5% dextrose, and injected into the rabbit’s vitreous at 10, 55, 100, 550, or 1000 µg in 50 µL vehicle per eye, to determine the highest nontoxic dose. The dose, 100 µg, was injected into 24 rabbit eyes, to evaluate pharmacokinetics; into 14 rabbit eyes with established HSV retinitis, to evaluate its efficacy; and into 58 rabbit eyes before herpes simplex virus (HSV) infection to evaluate its intraocular antiviral duration.

RESULTS. Microfluidized particles of HDP-P-GCV showed an increased drug release rate compared with the large-particle drug formulation, with area under concentration-time curve (AUC) of 219.8 ± 114.1 (n = 3) versus 108.3 ± 47.2 (n = 3) for unmodified HDP-P-GCV during the 12-week period after a 2.8-micromole intravitreal injection. There was a 103% increase of the drug released from the microfluidized formulation of HDP-P-GCV versus the unmodified formulation. Intravitreal injections of HDP-cCDV at doses of 100 µg/eye or lower were not toxic. After the 100 µg/eye injections, HPLC analysis showed a vitreous HDP-cCDV level of 0.05 µM at week 5, which declined to 0.002 µM at week 8. The concentration at week 8 (0.002 µM) remained above the IC₅₀ for cytomegalovirus (0.0003 µM). The pretreatment study demonstrated an antiviral effect that lasted 100 days after a single intravitreal injection.

CONCLUSIONS. This crystalline lipid prodrug intravitreal delivery system is an effective approach to achieving sustained, therapeutic drug levels in the eye. Small microfluidized particles of HDP-P-GCV provide more rapid dissolution and higher vitreous drug levels.

This article has been cited by other articles:

				L Cheng, E Anglin, F Cunin, D Kim, M J Sailor, I Falkenstein, A Tammewar, and W R Freeman Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle Br. J. Ophthalmol., May 1, 2008; 92(5): 705 - 711. [Abstract] [Full Text] [PDF]

				I. Kozak, L. Cheng, G. A. Silva, and W. R. Freeman Testing of Intraocular Drugs for Clinical Use Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4861 - 4863. [Full Text] [PDF]